Avantor reported second quarter 2026 net sales of $1,692.3 million and diluted GAAP EPS of $0.06. The company updated its full-year fiscal 2026 guidance, raising the organic revenue growth range to -0.5% to +0.5% from a previous forecast of -2.5% to -0.5%, while maintaining adjusted EPS guidance at $0.80 to $0.83. Management highlighted improved performance in the VWR Distribution and Services segment, which returned to positive organic growth ahead of schedule. Avantor operates as a global provider of mission-critical products and services to customers in the life sciences and advanced technology industries.

On July 14, 2026, Avantor Funding, Inc., a subsidiary of Avantor, Inc., entered into Amendment No. 15 to its Credit Agreement to obtain €374,208,296.62 in senior secured Euro-denominated term loans (Incremental B-7 Euro Term Loans). These loans, maturing October 9, 2032, carry an interest rate of the floating EURIBOR Rate plus 2.00% per annum, effectively refinancing existing euro term loans that carried a higher spread of 2.50%. The new loans are secured by the same collateral and guaranteed by the same subsidiaries as the existing credit facilities. Avantor operates in the life sciences industry, providing products and services to customers in the biopharma, healthcare, education, and government sectors.